Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 26.
doi: 10.1038/s41409-025-02674-3. Online ahead of print.

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy

Marta Lisa Battista  1 , Gabriele Facchin  2 , Maria De Martino  3 , Patrizia Chiusolo  4   5 , Domenico Russo  6 , Michele Malagola  6 , Francesco Saraceni  7 , Giorgia Mancini  7 , Alessandro Rambaldi  8 , Irene Maria Cavattoni  9 , Albana Lico  10 , Chiara Nozzoli  11 , Angela Cuoghi  12 , Marco Ladetto  13 , Vincenzo Federico  14 , Maria Caterina Micò  15 , Maria Teresa Lupo-Stanghellini  16 , Elena Oldani  8 , Eliana Degrandi  17 , Anna Maria Gallina  18 , Matteo Parma  19 , Alessandra Biffi  20 , Franca Fagioli  21 , Cristina Skert  22 , Antonella Geromin  2 , Chiara Savignano  23 , Miriam Isola  3 , Renato Fanin  2   3 , Fabio Ciceri  16   24 , Massimo Martino  15 , Francesca Patriarca  2   3
Affiliations

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy

Marta Lisa Battista et al. Bone Marrow Transplant. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: FP participated in Advisory Board of Menarini, Sanofi, Bristol Meyer Squibb and received lecture honoraria from Johnson&Johnoson and Novartis. MTLS participated in Advisory Board of Novartis, Pfizer, consultancy Incyte, Sanofi, other (organization of scientific event) Therakos / Mallinkrodt. AL participated in AbbVie Speakers Bureau. All other authors declared no potential competing interests in relation to this study. Ethics approval and consent to participate: Patient and transplant data were extracted from the European PROMISE database and additional queries were then submitted to each center to try to minimize missing data. All patients included in the study provided informed consent to data registration in the PROMISE database. The study, conducted in accordance with good clinical practice guidelines and regulations, was approved by the GITMO Trial Office and by the Institutional Review Board of Udine University (Prot. IRB 145/2024).

References

    1. Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–15.
    1. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10. - PubMed
    1. Malagola M, Cancelli V, Skert C, Ferremi Leali P, Tiburzi A, sala ML, et al. Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an italian multicentric retrospective analysis on 94 patients on behalf of the gruppo italiano trapianto di midollo osseo. Transplantation. 2016;100:147–55.
    1. Pierelli L, Perseghin P, Marchetti M, Messina C, Perotti C, Mazzoni A, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion. 2013;53:2340–52. - PubMed
    1. Pierelli L, Bosi A, Olivieri A. “Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion. 2018;58:217–22. - PubMed

LinkOut - more resources